

Ordering High Titer Convalescent Plasma for an Immunocompromised Patient With Active COVID-19

WHAT	WHY	ORDER	ADMINISTER	RESOURCES
<p>High titer Convalescent Plasma (CP) has received Emergency Use Authorization (EUA) from the US FDA to treat immunocompromised (IC) patients.</p> <p>It can be administered in either the outpatient or inpatient setting.</p> <p>U.S. Food & Drug Administration expands EUA of convalescent plasma with high titers of anti-SARS-CoV-2 antibodies for immunocompromised patients.</p>	<p>Convalescent plasma from patients who were vaccinated and recovered from a breakthrough infection is very high titer, polyclonal, and covers emerging COVID-19 variants that have escaped monoclonal antibodies.</p> <p>High titer CCP is replacement therapy for immunosuppressed patients who have challenges making natural antibodies and/or responding to COVID-19 vaccines.</p>	<p>To order high titer CCP for an IC patient:</p> <ol style="list-style-type: none"> 1. Contact the local blood collector (eg, OneBlood, Vitalant) that serves your hospital. 2. Ask how to order blood products. If this is going to be an outpatient transfusion, an outpatient transfusion center will need to be identified. 3. If there is no high titer CCP available at your locale, request they facilitate a search for it. 4. Use CMS billing: HCPCS code C9507 for administering in the outpatient setting. 	<p>Generally:</p> <p>Start with administration of 2 units of high titer CCP from separate donors and, if appropriate, with concurrent administration of remdesivir.</p> <p>Monitor PCR cycle time results before and after treatment. If this is done, measure PCR cycle time 7 days after administration.</p> <p>If PCR cycle times are below 30 after 7-10 days, it is reasonable to transfuse and additional 1-2 units of high titer CCP and repeat the PCR CT testing in 7 additional days.</p>	<p>Slide deck: Efficacy of high titer CCP in the treatment of COVID-19, including its utility in IC patients.</p>  <p>Short VaxCCP in immunocompromise</p> <p>Journal article: Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19</p> <p>Billing & payment information/claims submission.</p> <p>Email questions</p>